Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Women—especially Black women—are underrepresented in late-stage studies of new HIV therapies.
The company will resume development of islatravir for HIV treatment but abandons monthly oral PrEP.
The documentary short “Right to Try” follows Jeffrey Drew as he participates in an experimental and controversial treatment to cure HIV.
Studies of islatravir are put on hold after participants experience declining CD4 and lymphocyte counts.
Early treatment is linked to a smaller viral reservoir, but blocking IL-10 and PD-1 might control the virus in those with chronic infection.
The novel HIV capsid inhibitor also shows promise for previously untreated people.
The government-wide effort aims to develop the next generation of COVID-19 treatments to prepare the U.S. to respond to future virus threats
An islatravir PrEP implant could prevent HIV for a year.
A Brazilian man with HIV is no longer in remission after more than 15 months off treatment.
Molnupiravir, previously studied for hepatitis C, might be able to prevent or treat COVID-19 outside of a clinical setting.
The São Paulo Patient is no longer HIV-free after more than 15 months off treatment, but was it a relapse or reinfection?
A next-generation implant maintained adequate drug levels for at least a year in an early study.
MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.
None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.